Avenzo Therapeutics has released early Phase 1 data on AVZO-021, a selective cyclin-dependent kinase 2 (CDK2) inhibitor, in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. The results, presented at the 2025 San Antonio Breast Cancer Symposium, suggest preliminary signs of clinical activity in patients previously treated with CDK4/6 inhibitors, alongside a safety profile that may support further development in combination settings.

What the early data suggests about CDK2 as a resistance target

The emergence of CDK2 as a therapeutic target in HR+/HER2- breast cancer reflects an evolving understanding of how tumors adapt to CDK4/6 inhibition. As first-line CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib become entrenched in standard treatment, relapse driven by upregulation of cyclin E and CCNE1 amplification is increasingly observed. These pathways converge on CDK2 activity, allowing tumor cells to circumvent cell cycle arrest despite upstream blockade.

By selectively inhibiting CDK2, AVZO-021 aims to disrupt this resistance mechanism. The Avenzo Therapeutics approach contrasts with pan-CDK inhibition strategies that historically produced toxicities limiting their clinical utility. Industry analysts note that if AVZO-021 can sustain tolerability and demonstrate efficacy in post-CDK4/6 settings, it may fill a critical gap in treatment sequencing for HR+/HER2- disease.

Why the safety and tolerability profile may widen combination opportunities

The Phase 1 study enrolled 45 patients across monotherapy and combination cohorts, with a median of three prior lines of therapy. Despite the heavily pretreated population, the majority of treatment-emergent adverse events were Grade 1 or 2, including nausea, fatigue, anemia, and vomiting. No treatment discontinuations due to adverse events were reported.

This safety profile stands out when compared with earlier-generation CDK inhibitors, many of which suffered from overlapping hematologic and gastrointestinal toxicity. Clinical investigators suggest that tolerability at pharmacologically active doses is critical for combination regimens involving endocrine therapy or other kinase inhibitors. In this context, Avenzo Therapeutics is now evaluating AVZO-021 alongside fulvestrant and preparing for trials with AVZO-023, its selective CDK4 inhibitor.

The lack of observed drug-drug interaction at 150 mg daily doses supports this combination strategy. Pharmacokinetic data also demonstrated sustained target coverage at doses of 90 mg and above, providing a foundation for rational dose optimization in subsequent cohorts.

What the efficacy signals reveal—and what remains unclear

Among the 19 efficacy-evaluable patients treated with AVZO-021 monotherapy, three achieved confirmed partial responses. Two of these occurred in patients with HR+/HER2- breast cancer, and one in a patient with CCNE1-amplified ovarian cancer. Onset of response ranged from 15 to 36 weeks. An additional seven patients achieved stable disease, including six with HR+/HER2- tumors, with many still on treatment.

In the combination arm with fulvestrant, one of nine evaluable patients experienced a confirmed response by week seven. Three others achieved stable disease and continue treatment. Notably, all confirmed responders remain on therapy, with two exceeding 48 weeks.

While these findings are encouraging, particularly in a population previously treated with CDK4/6 inhibitors, the data remain too limited to draw conclusions about response durability or population-wide benefit. No progression-free survival, duration-of-response, or objective response rate metrics were reported. Additionally, the absence of subgroup analyses based on biomarkers such as CCNE1 status limits interpretation of which patients may benefit most.

Why Avenzo’s dual CDK strategy could offer modularity over existing regimens

Unlike current CDK4/6 inhibitors that target both kinases simultaneously, Avenzo Therapeutics is pursuing a modular approach with selective inhibition of CDK4 (AVZO-023) and CDK2 (AVZO-021) in parallel. This strategy enables more tailored combinations, potentially allowing oncologists to adapt regimens based on resistance profiles or tolerability concerns.

Regulatory experts note that such an approach could allow finer control over dose titration and toxicity management, particularly in patients who fail on dual CDK4/6 agents. However, the complexity of developing and validating multiple agents in tandem may pose logistical and regulatory hurdles, including manufacturing coordination and trial design.

Furthermore, without head-to-head comparisons with existing CDK4/6 therapies or other CDK2 inhibitors in development, AVZO-021 will need to demonstrate clear advantages in both efficacy and tolerability to carve out market relevance.

Why ctDNA reductions and biomarker signals could drive future validation

One of the more forward-looking aspects of the dataset involves the observed decreases in circulating tumor DNA (ctDNA), a dynamic biomarker increasingly viewed as a surrogate for clinical response in solid tumors. While Avenzo Therapeutics did not release detailed ctDNA kinetics or molecular correlates, the presence of ctDNA declines in patients with radiographic responses supports further exploration of this biomarker.

Experts in the field believe ctDNA-based response tracking could accelerate go/no-go decisions in early-phase trials and provide a non-invasive means to monitor resistance evolution. If future analyses confirm that ctDNA reduction correlates with longer-term outcomes, this may strengthen the rationale for biomarker-driven patient selection.

What hurdles remain before AVZO-021 can claim best-in-class potential

Despite the enthusiasm, Avenzo Therapeutics faces several critical challenges before AVZO-021 can be considered a best-in-class CDK2 inhibitor. First, the drug must differentiate itself from earlier CDK2 agents that failed due to narrow therapeutic windows. Second, it will need to demonstrate superior activity in randomized settings, particularly in comparison to combination regimens already supported by long-term outcome data.

Another concern lies in regulatory timing. If AVZO-021 is to be positioned as part of a combination backbone, the success of AVZO-023 becomes intertwined with its future. Any delays or setbacks in the CDK4 program could impact AVZO-021’s commercial and clinical trajectory.

Additionally, cost and reimbursement will weigh heavily on adoption. Health payers may hesitate to reimburse combination regimens without clear progression-free or overall survival benefits. As more targeted agents crowd the HR+/HER2- landscape, demonstrating both additive efficacy and cost-effectiveness will be crucial.

What industry stakeholders will watch as Avenzo moves into next-phase development

Looking ahead, clinical trialists and analysts will closely monitor several key questions. Will Avenzo Therapeutics pursue biomarker enrichment strategies in future studies, focusing on CCNE1-amplified or CDK4/6-resistant subsets? Can AVZO-021 show sufficient single-agent activity to justify continued monotherapy development? And will the dual-CDK combination prove safe and tolerable in larger cohorts?

The San Diego-based biotechnology company has positioned its oncology pipeline around selectivity, modularity, and post-resistance mechanisms. With AVZO-021 now showing its first signs of traction, the next 12 months may determine whether this CDK2 program can deliver the durable clinical benefit needed to move beyond niche status and into broader clinical utility.

  Avenzo Therapeutics, AVZO-021, CDK2 inhibitor, CDK4/6 resistance, ctDNA, fulvestrant, HR+/HER2- breast cancer, kinase inhibitors, oncology, Phase 1/2 trial